Fennec Pharmaceuticals Inc. (FENC)
| Market Cap | 430.27M +71.0% |
| Revenue (ttm) | 59.22M +77.8% |
| Net Income | -3.25M |
| EPS | -0.10 |
| Shares Out | 35.07M |
| PE Ratio | n/a |
| Forward PE | 19.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 421,787 |
| Open | 11.71 |
| Previous Close | 11.77 |
| Day's Range | 11.60 - 12.51 |
| 52-Week Range | 5.65 - 13.25 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 17.67 (+44.01%) |
| Earnings Date | Aug 11, 2026 |
About FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of oto... [Read more]
Financial Performance
In 2025, Fennec Pharmaceuticals's revenue was $44.64 million, a decrease of -6.09% compared to the previous year's $47.54 million. Losses were -$9.74 million, 2134.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price target is $17.67, which is an increase of 44.01% from the latest price.
News
Fennec price target raised to $16 from $13 at Wedbush
Wedbush raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps an Outperform rating on the shares. The firm notes Q2 PEDMARK revenue of $17.2M exceeded…
Fennec price target raised to $18 from $16 at B. Riley
B. Riley raised the firm’s price target on Fennec (FENC) to $18 from $16 and keeps a Buy rating on the shares. The Q2 results de-risk a potential 2H26 revenue…
Fennec Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue grew 78% year-over-year to $17.1 million, with record patient enrollments and infusions driving the seventh consecutive quarter of growth. Expanded commercial and medical teams, innovative awareness campaigns, and strong cash flow position the business for continued momentum.
Fennec Pharmaceuticals Earnings release: Q2 2026
Fennec Pharmaceuticals released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Fennec Pharmaceuticals Quarterly report: Q2 2026
Fennec Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 11, 2026.
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced tha...
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...
Fennec Pharmaceuticals Transcript: AGM 2026
Record sales and financial strength marked 2025, with major growth in PEDMARK and expansion into new markets. All shareholder proposals passed, including board elections and equity plan amendments. Strategic initiatives target broader clinical adoption and global reach.
Fennec price target raised to $16 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps a Buy rating on the shares. Pedmark adoption continues to build across both new…
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
PEDMARK, the only approved agent to prevent cisplatin-induced hearing loss, is expanding from pediatrics into the larger AYA market, driving record revenues and broader adoption. Ongoing real-world studies and global partnerships aim to unlock further growth and long-term exclusivity.
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that...
Fennec Pharmaceuticals Slides: Corporate presentation
Fennec Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Fennec Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 73% year-over-year sales growth, driven by commercial expansion and strong demand in key cancer segments. Operational improvements led to record infusions and high conversion rates, while new clinical studies and international launches are set to support further growth.
Fennec Pharmaceuticals Earnings release: Q1 2026
Fennec Pharmaceuticals released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Fennec Pharmaceuticals Quarterly report: Q1 2026
Fennec Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
Fennec reports Q1 EPS 1c, consensus (2c)
Reports Q1 revenue $15.1M, consensus $13.84M. “We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec (FENC), with growing…
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ...
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Proxy statement: Proxy filing
Fennec Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Fennec Pharmaceuticals Slides: Corporate presentation
Fennec Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigatio...
Fennec Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 sales and robust AYA growth drove a 50% revenue increase, supported by expanded teams, new clinical evidence, and a strengthened balance sheet. U.S. exclusivity for PEDMARK is secured through 2033, with major European launches and further growth expected in 2026.